1375 results about "Phosphorylation" patented technology

Aspects of the disclosure relate to complexes and other aspects relate to formulations (e.g., aqueous, lyophilized forms) comprising such complexes (e.g., wherein each complex is of the exemplary formula shown below) comprising a phosphorodiamidate morpholino oligomer (e.g., useful for targeting DMD) covalently linked to an antibody (e.g., anti-TfR1 antibody). In some embodiments, the complexes are formulated with histidine (e.g., L-histidine) and sucrose at a specified pH (e.g., about 5.0 to 7.0). Also provided are uses of these formulations for treating a subject having a mutated DMD allele associated with Duchenne Muscular Dystrophy.

The invention provides a monoclonal antibody of a p-Tau217 protein and an application of the monoclonal antibody. In particular, the present invention provides an antibody or an antigen binding fragment thereof targeting a p-Tau217 protein. The antibody provided by the invention can specifically recognize and bind the p-Tau217 protein, does not recognize p-Tau181 and non-phosphorylated Tau protein, and can be used for preparing a detection preparation or a kit for diagnosing diseases related to the p-Tau217 protein, such as Alzheimer's disease.

The invention belongs to the field of functional proteomics research, and particularly relates to a combined analysis method for analyzing interaction between a small molecule substance and a targeted protein, which is used for analyzing the small molecule substance and the protein by adopting LiP-MS (Limited Protein-Mass Spectrometry) technology and phosphorylated proteome combined analysis. According to the method, the optimized LiP-MS technology is adopted, the target protein can be directly recognized under the complex proteome background without enriching specific protein, and the problem that low-abundance protein is difficult to detect is solved; phosphorylated proteome abundance transformation protein is analyzed by combining high-resolution mass spectrometry, so that the recognition capability on a drug target and a shear variant thereof is enhanced, and the detection sensitivity is improved.

The invention belongs to the technical field of mineral processing, and particularly relates to a synthetic method and application of a carboxymethyl-phosphorylated bifunctional chitosan inhibitor. The synthetic method of the carboxymethyl-phosphorylated bifunctional chitosan inhibitor comprises the following steps: (1) carrying out acid activation pretreatment; (2) phosphorylation reaction; (3) carboxymethylation modification; and (4) carrying out solid-liquid separation and drying. The invention also provides an application of the carboxymethyl-phosphorylated bifunctional chitosan inhibitor. According to the synthetic method of the carboxymethyl-phosphorylated bifunctional chitosan inhibitor disclosed by the invention, the synthesized carboxymethyl-phosphorylated chitosan inhibitor realizes the function switching of'two states in one dose ', the tedious operation of frequently replacing medicaments in the traditional process is avoided, and meanwhile, the medicament residue interference is eliminated.

The invention relates to the technical field of biological medicines, and provides a novel DELTP polypeptide and application thereof in improving cTnI cardiovascular medicines, and a novel polypeptide and application thereof in medicines for treating cardiovascular diseases. The polypeptide has a unique amino acid sequence and is composed of an amino acid sequence SEQ. NO: 1: Asp-Glu-Leu-Thr-Pro (DELTP), an amino acid sequence SEQ. NO: 2: Arg-His-Met-Ser-Tyr (RHMST) and the like, and the cardiovascular function is improved by adjusting the phosphorylation level of cardiac troponin I (cTnI).

The invention relates to the technical field of biology, in particular to a gene for increasing the content of resveratrol in grapes and application of the gene. The invention discloses a gene for improving the content of resveratrol in grapes. The DNA sequence of the gene is shown as SEQ ID NO1. The amino acid sequence of the gene synthetic protein disclosed by the invention is as shown in SEQ ID NO2, and the protein is named as VvFHY34D. According to the invention, when four amino acids S124, T128, S156 and T160 of the VvFHY3 are all replaced with aspartic acid to simulate phosphorylation activation, the VvSTS expression quantity in transient over-expression VvFHY34D grapes is higher, and more resveratrol can be synthesized.

[Problem] To provide a complex compound useful as a catalyst for a hydrophosphorylation reaction and a process for producing the same.[Means to Solve the Problem] A complex compound of the present invention is a complex compound of a resin fine particle represented by the following general formula (1):wherein, R1 represents a substituted or unsubstituted hydrocarbon group, R2 represents a substituted or unsubstituted alkyl group or a substituted or unsubstituted aryl group, R3 and R4 each independently represent a hydrogen atom, a substituted or unsubstituted alkyl group or a substituted or unsubstituted aryl group, and based on the total of 100% of the values of n and m, the value of n is within the range of 20 to 100%, the value of m is within the range of 0 to 80%, and * represents bonding with the surface of the resin fine particle and a transition metal.

The invention discloses a magnetic particle chemiluminiscence detection kit for human non-phosphorylated Tau217 protein and a preparation method of the magnetic particle chemiluminiscence detection kit. The kit comprises a micro magnetic particle coupled with a human non-phosphorylated Tau217 protein capture antibody, an acridinium ester labeled human non-phosphorylated Tau217 protein detection antibody, a human non-phosphorylated Tau217 protein calibration product and a quality control product. The direct chemiluminescence method established by the invention has the advantages of high sensitivity, strong specificity, accuracy, rapidness and short detection time, the detection result has higher accuracy and repeatability, and the kit can be used for various luminescence detection instruments.

The invention discloses application of L-kynurenine in treatment of immune checkpoint inhibitor related myocarditis, and belongs to the field of biological medicine. It is found that by improving the level of L-kynurenine, phosphorylation of a JAK1 / STAT3 pathway of macrophages can be inhibited, proliferation of Tregs cells is promoted, and the progress of immune checkpoint inhibitor-related myocarditis is relieved; when the L-kynurenine is used for treatment, the immune checkpoint inhibitor related myocarditis caused by the PD-1 inhibitor can be obviously improved. Therefore, the L-kynurenine plays an important role in improving the immune checkpoint inhibitor related myocarditis and is expected to be developed into a medicine for treating the immune checkpoint inhibitor related myocarditis.

The present invention provides methods of reducing oncogene transcription, or of reducing phosphorylated RNA polymerase 2, in a subject in need thereof by administering to the subject of Compound (I), or a pharmaceutically acceptable salt thereof.

The disclosure relates to methods and kits for detecting tau, e.g., tau that is phosphorylated at amino acid position T181 (pTau181), tau that is phosphorylated at amino acid position T217 (pTau217), and / or total tau. The disclosure further provides methods for distinguishing between individuals whose cognitive condition will remain stable and whose cognitive condition will decline during their lifetime. The disclosure also provides methods for determining the eligibility of individuals for participation in clinical trials for Alzheimer's disease treatments. Also provided are methods for distinguishing between individuals with Alzheimer's disease and non-Alzheimer's dementia, and for monitoring response to treatment for Alzheimer's disease.

The invention provides a uracil production strain and a construction method and application thereof.According to the strain, on an E.coli UR14 genome by means of a CRIPSR / Cas9 gene editing technology, firstly, psuG genes, preTA genes, rutA genes and upp genes are knocked out, so that decomposition of uracil is blocked; then, a uridine phosphorylase gene udp and a pyrimidine-5 '-nucleotide nucleotidase gene ppnN are subjected to overexpression, and synthesis and accumulation of uracil are synergistically enhanced; and finally, overexpression of the ribose phosphate mutase gene pgm further enhances the conversion of a by-product ribose phosphate 1-precursor 5-ribose phosphate 1-pyrophosphate and improves the carbon utilization rate, and the obtained strain has good genetic stability and high fermentation yield, can stably produce uracil, and has wide application prospects.

The invention discloses a deoxyribozyme probe for identifying carbapenem-resistant klebsiella pneumoniae and application of the deoxyribozyme probe, and belongs to the technical field of deoxyribozyme probes. The method comprises the following steps: firstly, mixing a phosphorylated library chain, a substrate chain and a connecting chain, then, carrying out covalent linkage to construct a DNA library, firstly, carrying out reverse screening, separating and purifying a DNA band of an uncut substrate RNA site, constructing a chain-shaped DNA library by using the obtained DNA band, carrying out forward screening, separating and purifying the DNA band of the cut substrate RNA site, carrying out PCR (Polymerase Chain Reaction) amplification, and recovering a positive-sense chain, so as to obtain the DNA library. The deoxyribozyme probe is obtained by performing repeated screening and enriching, and the probe can recognize carbapenem-resistant klebsiella pneumoniae with high specificity and has the potential of exerting advantages in the aspect of biosensing application.

The method for preparing D-mannose through catalysis can effectively reduce the amount of by-products glucose and fructose, and greatly improves the conversion rate of D-mannose. Specifically, engineering bacteria for expressing isoamylase genes and engineering bacteria for expressing alpha-glucan phosphorylase genes, glucophosphate mutase genes, difunctional enzyme glucophosphate isomerase / mannose 6-phosphate isomerase genes and mannose 6-phosphate phosphatase genes are utilized, starch or starch derivatives are used as substrates, and the starch or starch derivatives are used as substrates. A phosphate buffer solution and Mg < 2 + > are added, a preliminary catalysis system is constructed, after the reaction is completed, an incompletely-reacted substrate and maltodisaccharide exist in the reaction system, the incompletely-reacted substrate and maltodisaccharide can be hydrolyzed into glucose by glucoamylase, and the polyphosphoglucokinase can be used for catalyzing the reaction of the polyphosphoglucokinase under the assistance of sodium hexametaphosphate. All glucose is converted into phosphorylated glucose, then D-mannose is generated, and by-products in a system are removed while the yield is increased.

The invention provides application of scEMC10 in treatment and diagnosis of cerebral vascular endothelial cell senescence, and relates to the technical field of biomedicine. The research of the inventor finds that brain microvascular endothelial cell senescence is caused by the lack of scEMC10; after the brain microvascular endothelial cells are treated by scEMC10, beta-galactosidase, SASP and classic senescence markers related to senescence can be down-regulated; after scEmc10 is supplemented to old mice and Alzheimer's disease 5XFAD model mice, the motion coordination ability and the spatial cognitive ability of the mice can be obviously improved, the relative content of a marker phosphorylated alpha-synuclein of the Parkinson's disease of the old mice can be obviously reduced, and the content of tyrosine hydroxylase phosphorylated active forms can be increased. Therefore, the scEMC10 can be used for treating brain microvascular endothelial cell senescence, improving Alzheimer's disease and Parkinson's disease and detecting brain microvascular endothelial cell senescence as a marker.

The invention provides an Auricularia auricula polysaccharide, its application and preparation method thereof, which belong to the technical field of improving polysaccharide. After being degreased, the Auricularia auricula is subjected to preliminary enzymolysis under the effect of helicase, is further subjected to deep enzymolysis under the effect of complex enzyme through synergetic ultrasound-assisted degradation and extraction with H2O2, and is subjected to mixed fermentation by Lactobacillus bulgaricus, Streptococcus thermophilus and Bifidobacterium longum, the obtained fermented Auricularia auricula polysaccharide is subjected to a phosphorylation reaction under the effect of a phosphorylation reagent, and after further deproteinization and decolorization, the obtained fermented Auricularia auricula polysaccharide is chelated with zinc salt to obtain a polysaccharide-zinc compound, and the amount of the extracted Auricularia auricula polysaccharide is improved. The finished product of the invention has the effects of reducing blood sugar and blood fat, regulating total cholesterol and effectively improving HDL cholesterol.

The invention belongs to the technical field of bioengineering, and particularly relates to a sucrose phosphorylase mutant and application thereof in synthesis of 2-O-alpha-D-glucopyranosyl-L-ascorbic acid. The sucrose phosphorylase mutant is obtained by simultaneously mutating multiple sites of amino acids at the 91st site, the 154th site, the 185th site, the 323rd site and the 424th site of wild sucrose phosphorylase derived from Bifidobacterium pseudolongum, so that the efficiency of producing 2-O-alpha-D-glucopyranosyl-L-ascorbic acid by taking sucrose and vitamin C as raw materials is remarkably improved; only 15 hours are needed for completely catalyzing 1.2 M of vitamin C to produce 2-O-alpha-D-glucopyranosyl-L-ascorbic acid; and the yield of the 2-O-alpha-D-glucopyranosyl-L-ascorbic acid reaches 358 g / L. Therefore, the 2-O-alpha-D-glucopyranosyl-L-ascorbic acid has an important application value in the field of production of the 2-O-alpha-D-

The invention relates to the technical field of biological information, and discloses a multi-mode phosphorylation site prediction method and device, equipment and a medium, and the method comprises the steps: extracting a subsequence of a candidate phosphorylation site from a to-be-predicted protein sequence, and generating a sequence feature of the subsequence through a deep learning model; constructing a graph structure based on the three-dimensional structure information of the candidate phosphorylation sites, and extracting structural features of the candidate sites through a graph neural network according to the graph structure; performing multi-modal feature fusion on the sequence features and the structural features to generate fusion features; and predicting the phosphorylation probability of the candidate site based on the fusion feature to obtain a phosphorylation probability prediction result. According to the method, the protein sequence language model and the multi-modal features of the three-dimensional structure diagram convolutional network are fused, so that the accuracy and comprehensiveness of phosphorylation site prediction can be effectively improved, and meanwhile, the calculation efficiency and the bioinformatics interpretation are considered.

The invention belongs to the field of artificial intelligence algorithm application-biological sequence recognition, and relates to a method for recognizing phosphorylation modification sites based on a large model technology. According to the method, the latest protein large model technology ESM-2 is applied to the phosphorylation modification site recognition direction, the current forefront technology is fully utilized to recognize the phosphorylation modification site infected by SARS-CoV-2, and the recognition accuracy and reliability are remarkably improved. According to the method, the intermediate output of the protein pre-training large model is innovatively extracted for subsequent research. For different tasks, different level output features may be needed, the research provides a clear example, and the effectiveness of model intermediate layer output is displayed. According to the method, transfer learning related technologies are creatively used, so that the problem that classification prediction cannot be effectively carried out due to the fact that tyrosine (Y) data in SARS-CoV-2 infected phosphorylation modification sites are rare is effectively solved.

The invention discloses a kit for jointly detecting phosphorylated Tau-217 and non-phosphorylated Tau-217. The kit comprises a magnetic microsphere reagent, a detection antibody reagent and a fluorescent microsphere reagent, the magnetic microsphere reagent comprises a magnetic microsphere compound, the detection antibody reagent comprises a first detection antibody compound and a second detection antibody compound, and the fluorescent microsphere reagent comprises a first fluorescent microsphere compound and a second fluorescent microsphere compound. The invention provides a kit for jointly detecting phosphorylated Tau-217 and non-phosphorylated Tau-217, which is based on a single molecule detection technology, and realizes accurate distinguishing and high-sensitivity detection on the phosphorylated Tau-217 and the non-phosphorylated Tau-217 at the same time through a double-target synchronous detection design and a double-color fluorescence report system.

The invention discloses a method for preparing inositol, particularly relates to a method for converting glucose into inositol through in-vitro multi-enzyme catalysis, and belongs to the field of enzyme catalysis preparation of inositol. According to the invention, the phosphoglucose synthase capable of realizing phosphorylation of glucose by using inorganic phosphate is screened, and the inositol can be generated through conversion by taking glucose as a substrate, so that a novel method for synthesizing the inositol through enzyme catalytic conversion is provided. In addition, the invention further provides hexokinase capable of improving the yield of inositol, and the conversion efficiency of glucose is greatly improved. Furthermore, the invention provides a multi-enzyme molecular machine containing the glucose phosphate synthase and / or hexokinase, the multi-enzyme molecular machine is applied to preparation of inositol, and the reaction steps are simple, green and pollution-free.

The present disclosure relates in some aspects to methods for analyzing a target nucleic acid in a biological sample (e.g., cell or tissue sample). In some aspects, provided herein are methods and compositions for analyzing a target nucleic acid in a ligation-based assay using one or more probes, and phosphorylation of one or more probes hybridized to a target nucleic acid is performed.

The invention relates to a TaCBL4 mediated TaSOS1 phosphorylation regulation and control site in wheat and an application of the TaCBL4 mediated TaSOS1 phosphorylation regulation and control site. The TaSOS1 phosphorylation regulation and control site is Ser978-Ser1126 / Ser1128 (S978-DSPS); the phosphorylation regulation and control site of the TaSOS1 is S978-DSPS, and serine at the site 978 of the TaSOS1-DAA (S1126AS1128A) is mutated into alanine. The TaSOS1 in the wheat is from a chromosome LOC778390, NC057800.1 (13146069..13157356) of the 3A of the common wheat, and the TaSOS1 in the wheat is from a chromosome NC057800.1 (13146069..13157356). The invention also relates to an application of the TaCBL4 mediated TaSOS1 phosphorylation regulation site Ser978-Ser126 / Ser128 (S978-DSPS) in the wheat as a molecular marker for detecting the salt tolerance of the wheat, and also relates to an application of the TaCBL4 mediated TaSOS1 phosphorylation regulation site. The site is applied to the aspects of wheat salt tolerance improvement and assisted breeding.

The invention provides a traditional Chinese medicine compound for treating sicca syndrome and a preparation method and application thereof, and belongs to the technical field of traditional Chinese medicine compounds. The traditional Chinese medicine compound provided by the invention has the effects of eliminating dampness and heat, removing blood stasis and promoting salivation, can safely and effectively treat sicca syndrome by improving functions of exocrine glands and regulating immunity, belongs to a pure traditional Chinese medicine preparation, and has no toxic or side effect. The traditional Chinese medicine compound is proved to be capable of remarkably relieving the sicca syndrome, relieving dry mouth and eye symptoms of a patient, relieving fatigue, regulating and controlling a plurality of signals taking RAGE / TLR4 as a core, inhibiting excessive activation of an HMGB1-RAGE / TLR4-NF-kappa B pro-inflammatory pathway from gene and protein levels, inhibiting generation of pro-inflammatory cytokines, reducing inflammatory response and improving the immunity of the patient. The effect of treating the sicca syndrome is achieved. By acting on STAT3 phosphorylation, Tfh proliferation is inhibited, IL-21 secretion is reduced, humoral immune disorder is relieved, and the sicca syndrome is treated, so that the condition of the sicca syndrome is relieved, and the prognosis of the sicca syndrome is improved.

The invention provides a monoclonal antibody of a p-Tau181 protein and an application of the monoclonal antibody. Specifically, the invention provides an antibody targeting p-Tau181 protein or an antigen binding fragment of the antibody. The antibody provided by the invention can specifically recognize and bind the p-Tau181 protein, does not recognize p-Tau217 and non-phosphorylated Tau protein, and can be used for preparing a detection preparation or a kit for diagnosing diseases related to the p-Tau181 protein, such as Alzheimer's disease.

The invention provides a method for synthesizing D-psicose through fermentation of escherichia coli by using D-glucose and D-xylose. The method comprises the following steps: by taking escherichia coli as a host cell, over-expressing a galactose permease gene galP, a glucokinase gene glk, a 6-phosphate glucose isomerase gene pgi, a D-psicose-6-phosphate epimerase gene alsE with an SUMO tag and a D-psicose-6-phosphate phosphatase gene a6PP, and constructing a path for synthesizing D-psicose by taking D-glucose and D-xylose as substrates; the synthetic route of D-psicose is optimized by knocking out a D-glucose phosphorylation transport pathway gene ptsG, knocking out D-fructose-6-phosphokinase genes pfkA and pfkB, silencing a glucose-6-phosphate dehydrogenase gene zwf, overexpressing glutamate transhydrogenase genes gdh1 and gdh2, knocking out a UDP-glucose-4-epimerase gene galE and knocking out a transport protein key gene fryA in D-psicose; and finally, the optimal proportion of mixed sugar fermentation is explored, so that efficient synthesis of D-psicose from escherichia coli through mixed sugar fermentation of D-glucose and D-xylose is realized.

The present application relates to a pyridoxal kinase mutant, a recombinant expression vector and a microbial cell and their applications, and belongs to the technical field of biological catalysis. In order to solve the problem of low product concentration in existing enzyme catalysis, a pyridoxal kinase mutant is provided, the amino acid sequence is selected from the amino acid sequence shown in SEQ ID NO. 1, the lysine at position 229 is mutated to alanine, phenylalanine, methionine, arginine, threonine, histidine, serine, tyrosine, valine, leucine, isoleucine, proline, asparagine, aspartic acid or glutamic acid; the pyridoxal kinase mutant is used for catalyzing pyridoxal to synthesize pyridoxal phosphate, and a recombinant expression vector and a microbial cell can be further formed. The present application has good enzyme activity, high product conversion rate, high concentration of pyridoxal phosphate obtained, and the concentration of the product catalyzed by the wild-type pyridoxal kinase to phosphorylate pyridoxal is obviously improved.

The invention relates to the technical field of biological tissue adhesives, in particular to a biological tissue adhesive composition. The biological tissue adhesive composition comprises a powder A, a powder B and a powder C, wherein the powder A is obtained by curing calcium silicate and acidic calcium phosphate in a curing liquid, curing, drying and crushing; powder B: bivalent metal salt; powder C: phosphorylated amino acid; and an aqueous solvent; the biological tissue adhesive is used for bone adhesion and bone repair. According to the biological tissue adhesive composition provided by the invention, a silicate / hydroxyapatite composite material with a bone induction function is synthesized through optimized bone cement reaction, a curing liquid is added to react with phosphorylated amino acid, and a bone adhesive material is obtained through organic and inorganic material coordination reaction; the bone repairing and regenerating capability and the bone bonding capability are good.

The invention belongs to the technical field of triple negative breast cancer, and particularly relates to application of a polypeptide capable of specifically blocking phosphorylation of metabolic enzyme PSAT1S337 and functional remodeling of PSAT1 in preparation of a triple negative breast cancer treatment product. The phosphorylated polypeptide targeting PSAT1S337 is designed, and it is found that the polypeptide obviously inhibits growth of triple negative breast cancer tumors and can improve the curative effect of anti-PD-1 immunotherapy at the animal level. Meanwhile, the invention further provides application of the reagent for detecting the phosphorylation level of the PSAT1S337 and / or the hydroxylation level of the GPX4P159 in preparation of products for diagnosing and prognosing the triple negative breast cancer. The invention discloses a molecular mechanism of functional remodeling of the serine metabolic enzyme PSAT1 in occurrence and development of cell ferroptosis and triple negative breast cancer, and provides a new thought and an effective scheme for research and development of anti-tumor drugs for targeted serine metabolism reprogramming and early diagnosis of tumors.

The invention discloses a method for enhancing squalene synthesis through oil tea HMGR gene editing. According to the method, phosphorylation regulation and control sites Ser47 and / or Thr208 recognized by MAPK are targeted, and enzymatic activity inhibition is relieved and metabolic flux is enhanced by constructing phosphorylation resistance mutants (such as Ser-> Ala and Thr-> Val). The constructed editing vector can be introduced into camellia oleifera tissues in manners of PEG-mediated protoplast transient transfer, agrobacterium infection of calluses and the like, so that stable expression is realized. Experiments prove that the enzyme activity of HMGR in the editor is remarkably improved, the squalene accumulation amount is increased by 50% or above, the editing efficiency is high, expression is stable, and the method is suitable for high-value development of plant triterpenoid functional components and excellent strain breeding. The method also has the potential of popularization and application in other triterpenoid synthetic crops.